Companies › TBF Genie Tissulaire
5 active drug programs in 6 registered trials: 4 Phase 2, 2 Phase 3; Immunology, Ophthalmology, Genitourinary, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| treated umbilical vein allograft (UVT) surgical sling made from treated allogeneic umbilical vein | – | Phase 3 | Stress Urinary Incontinence in Women | May 2028 |
| Therapeutic lens + amniotic membrane | – | Phase 3 | Progressive Keratoconus | – |
| SclerFIX-IP Decellularized, viro-inactivated, freeze-dried allogeneic amniotic membrane graft for join | – | Phase 2 | Osteoarthritis Hand | Nov 2026 |
| SclerFIX Treated, devitalized and sterile umbilical cord amniotic membrane allograft for interposit | – | Phase 2 | Trapeziometacarpal Osteoarthritis | Mar 2028 |
| AMTRIX-D Decellularized, viro-inactivated amniotic membrane graft functioning as anti-adhesive barr | – | Phase 2 | Tendon Adhesion | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06034262 | SclerFIX-IP | Phase 2 | Osteoarthritis Hand | Immunology | Oct 2025 |
| NCT06450470 | Therapeutic lens + amniotic membrane | Phase 3 | Progressive Keratoconus | Ophthalmology | Nov 2025 |
| NCT06723782 | AMTRIX-D | Phase 2 | Tendon Adhesion | Other | Sep 2026 |
| NCT06038331 | SclerFIX-IP | Phase 2 | Osteoarthritis Hand | Immunology | Nov 2026 |
| NCT07435571 | SclerFIX | Phase 2 | Trapeziometacarpal Osteoarthritis | Immunology | Mar 2028 |
| NCT06678984 | treated umbilical vein allograft (UVT) | Phase 3 | Stress Urinary Incontinence in Women | Genitourinary | May 2028 |
No annotated target.
–
Medipost Nature Cell Throne Biotechnologies Cellcolabs Clinical SPV EHL Bio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.